Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.78 |
| ▸ | LMNA | P02545 | 3/20 | 0.75 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.75 |
| ▸ | TSHR | P16473 | 1/20 | 0.75 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.75 |
| ▸ | MEN1 | O00255 | 1/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.69 |
| ▸ | THRB | P10828 | 1/20 | 0.68 |
| ▸ | CA2 | P00918 | 1/20 | 0.67 |
| ▸ | TP53 | P04637 | 1/20 | 0.63 |
| ▸ | MAPT | P10636 | 1/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25482066 | 0.89 | KMT2A (0.71) | KMT2ALMNASMN1; SMN2TSHRNPSR1 | |
| SCHEMBL25482068 | 0.86 | LMNA (1.00) | KMT2ALMNASMN1; SMN2TSHRNPSR1 | |
| SCHEMBL25481989 | 0.85 | ALDH1A1 (0.78) | KMT2ALMNANPSR1MEN1ALDH1A1 | |
| SCHEMBL25482017 | 0.84 | TSHR (0.81) | KMT2ALMNASMN1; SMN2TSHRNPSR1 | |
| SCHEMBL25482060 | 0.81 | KMT2A (0.74) | KMT2ALMNASMN1; SMN2TSHRNPSR1 | |
| SCHEMBL13241787 | 0.81 | KMT2A (0.73) | KMT2ALMNASMN1; SMN2MEN1ALDH1A1 | |
| SCHEMBL25482053 | 0.79 | KMT2A (0.74) | KMT2ALMNASMN1; SMN2TSHRNPSR1 | |
| SCHEMBL25482041 | 0.78 | TDP1 (0.76) | KMT2ALMNASMN1; SMN2TSHRNPSR1 | |
| SCHEMBL25481992 | 0.78 | SMN1; SMN2 (0.77) | KMT2ALMNASMN1; SMN2TSHRNPSR1 | |
| SCHEMBL25482008 | 0.77 | L3MBTL1 (0.78) | KMT2ALMNATSHRNPSR1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230158028-A1 | COMPOUNDS AND METHODS FOR INDUCING UCP1 EXPRESSION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-05-25 | — | — | US | disclosed |
| US-20230158028-A1 | COMPOUNDS AND METHODS FOR INDUCING UCP1 EXPRESSION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230158028-A1 | COMPOUNDS AND METHODS FOR INDUCING UCP1 EXPRESSION | TFAM, FABP4, CPT2 | KMT2A 2830/4885LMNA 688/4885SMN1; SMN2 4396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.